Últimas noticias sobre PACS Group (NYSE:PACS) Bolsa

PACS Group

PACS Group Inc is a post-acute healthcare company primarily focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.

PACS Group Inc

Iterum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRM#NASDAQ">ITRM</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Iterum Therapeutics to report an earnings per share (EPS) of $-0.23.
The market awaits Iterum Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.12, which was followed by a 0.0% drop in the share price the next day.

<img src="https://www.benzinga.com/files/images/story/2025/1747073325_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Iterum Therapeutics were trading at $1.02 as of May 09. Over the last 52-week period, shares are down 30.67%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ITRM/earnings">To track all earnings releases for Iterum Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

ITRM

A Look Ahead: Iterum Therapeutics's Earnings Forecast

BofA Securities analyst Justin Post maintained a Buy rating on Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) on Monday with a <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $230</a>.
Last week, Amazon announced eight new robots at its Delivering the Future event, including seven for its delivery stations and one for fulfillment centers, Post said.
Robots, including Tipper, ZancaSort, and Agility, can sort packages more efficiently, while Echelon and Vision-Assorted Sort Station can assist with handling.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/02/43972083/amazons-25-billion-robotics-push-targets-cost-savings-ai-growth-and-temu-competition-report" rel="noreferrer noopener">Amazon&#8217;s $25 Billion Robotics Push Targets Cost Savings, AI Growth And Temu Competition: Report</a>
In fulfillment centers, Vulcan can pick and stow items from pods using a combination of built-in conveyor belts and suction cups.
Vulcan can &#8220;feel&#8221; items with force feedback sensors and avoid damaging items. According to Amazon, robots help with about 75% of customer orders, but robot touchpoints per package will likely increase as Amazon introduces more robot types.
The post highlighted Amazon&#8217;s close to 1 million logistics and fulfillment employees, which can have 50% annual churn, and robotics can help solve potential long-term staffing bottlenecks.
On Amazon&#8217;s first-quarter earnings call, CEO Andy Jassy said robotics will be key to improving its cost structure, fine-tuning the company&#8217;s inbound network, and building out same-day delivery sites.
Post also noted that the cost savings enabled by robotics would open more rural areas to same-day delivery.
Robots can drive cost efficiencies by reducing labor costs, employee injury costs, higher utilization of Amazon&#8217;s warehouses, and order accuracy. This, in turn, decreases the number of product returns. Per MWPVL, returns can be approximately 20% of total fulfillment and delivery costs, the analyst said.
Amazon indicated that the company &#8220;is now ready to implement these innovations at scale,&#8221; though some robots will not likely launch until 2027.
Still, Amazon is already experimenting with robotics at its new 12 Generation Fulfillment Center, which opened in late 2024. This facility, located in Shreveport, Louisiana, spans more than 3 million square feet and houses 10 times more robots than previous generations.
According to Jassy, 12 Generation Fulfillment Centers can &#8220;reduce fulfillment processing time by up to 25%, increase the number of items we can offer for same-day or next-day delivery, and is expected to drive a 25% improvement in our cost to serve during peak&#8221;.
With fulfillment costs at $99 billion in 2024, even a 10% savings could add $10 billion in profits to the bottom line.
Amazon&#8217;s robotic efforts thus far have been mainly focused on fulfillment, which, according to Post, represents around 17% of Amazon&#8217;s total costs (and 15% of total revenues).
Delivery could be another area of material cost savings, with shipping costs representing another 17% of Amazon&#8217;s total costs (and 15% of total revenues).
With Zoox AV capabilities ramping up and more efficient MK30 drones launched late in 2024 (Amazon aims to deliver 500 million packages by drone annually by 2030), Post noted Amazon will also be able to find long-term cost savings in delivery, leveraging the company&#8217;s AI technical expertise.
Price Action: AMZN stock is up 7.9% at $208.49 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/03/44544278/softbank-looks-at-investing-1-trillion-for-us-ai-push-with-robot-run-industrial-parks" target="_blank" rel="noreferrer noopener">SoftBank Looks At Investing $1 Trillion For US AI Push With Robot-Run Industrial Parks</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

News

Price Target

Reiteration

Analyst Ratings

Trading Ideas

AMZN

Why Amazon's Robot Army Could Save $10 Billion And Change Your Delivery Game

WIIM

APGE

Apogee Therapeutics shares are trading higher after the company reported a Q1 EPS beat.

Truist Securities analyst Jake Bartlett maintains Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) with a Hold and raises the price target from $28 to $31.

Truist Securities Maintains Hold on Karat Packaging, Raises Price Target to $31

Hydrofarm Holdings Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYFM#NASDAQ">HYFM</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Hydrofarm Holdings Group to report an earnings per share (EPS) of $-2.10.
Anticipation surrounds Hydrofarm Holdings Group's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $1.38 in the last quarter, leading to a 5.23% drop in the share price on the following day.
Here's a look at Hydrofarm Holdings Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-2.42</td>
<td>-1.8</td>
<td>-2</td>
<td>-1.9</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-3.80</td>
<td>-2.9</td>
<td>-2.6</td>
<td>-2.8</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-5.0%</td>
<td>-4.0%</td>
<td>0.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747073277_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Hydrofarm Holdings Group were trading at $3.91 as of May 09. Over the last 52-week period, shares are down 59.41%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/HYFM/earnings">To track all earnings releases for Hydrofarm Holdings Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HYFM

What to Expect from Hydrofarm Holdings Group's Earnings

JP Morgan analyst Sebastiano Petti maintains BCE (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCE#TSX">BCE</a>) with a Underweight and raises the price target from C$28 to C$29.

TSX:BCE

JP Morgan Maintains Underweight on BCE, Raises Price Target to C$29

Truist Securities analyst Jamie Cook maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Hold and raises the price target from $130 to $141.

Truist Securities Maintains Hold on Jacobs Solutions, Raises Price Target to $141

Truist Securities analyst Richard Newitter maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Hold and lowers the price target from $80 to $68.

GMED

Truist Securities Maintains Hold on Globus Medical, Lowers Price Target to $68

Truist Securities analyst David Macdonald maintains Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Buy and raises the price target from $175 to $190.

Truist Securities Maintains Buy on Tenet Healthcare, Raises Price Target to $190

JP Morgan analyst Brian Essex maintains Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) with a Neutral and lowers the price target from $36 to $29.

JP Morgan Maintains Neutral on Rapid7, Lowers Price Target to $29

Evercore shares are trading higher after Keefe, Bruyette & Woods raised its price target on the stock from $238 to $257.

Truist Securities analyst David Macdonald maintains Pennant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNTG#NASDAQ">PNTG</a>) with a Hold and raises the price target from $28 to $32.

PNTG

Truist Securities Maintains Hold on Pennant Gr, Raises Price Target to $32

Truist Securities analyst David Macdonald maintains Labcorp Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) with a Buy and raises the price target from $274 to $290.

Laboratory Corporation Of America Holdings

Truist Securities Maintains Buy on Labcorp Hldgs, Raises Price Target to $290

JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Overweight and lowers the price target from $29 to $25.

CLBT

JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $25

Truist Securities analyst David Macdonald maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and lowers the price target from $325 to $305.

Truist Securities Maintains Hold on Humana, Lowers Price Target to $305

GRFS

Grifols shares are trading higher after the company provided Q1 financial results.

Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) has posted a 27% gain over the past week, with traders now expecting a much larger breakout. Despite a slight dip in whale activity, retail interest appears to be rising as Shibarium adoption continues <a href="https://www.benzinga.com/money/shiba-inu-price-prediction">and tokenomics improve.</a>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001610</td>
<td>$9.5 billion</td>
<td>+1.6%&nbsp;</td>
<td>&nbsp;+26.6%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2342</td>
<td>$34.95 billion</td>
<td>&nbsp;+2.3%</td>
<td>&nbsp;+37%</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001383</td>
<td>$5.8 billion</td>
<td>+2.7%&nbsp;</td>
<td>+74.5%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader CW sees Shiba Inu trying to break through the sell wall. If it breaks through, the next one is at $0.0000224.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24SHIB&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SHIB</a> is trying to break through the sell wall. If it breaks through the current sell wall, the next one is $0.0000224. <a href="https://t.co/pg7EwRD8uo">pic.twitter.com/pg7EwRD8uo</a>
&mdash; CW (@CW8900) <a href="https://twitter.com/CW8900/status/1921804434994020657?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to Coinpedia Markets, SHIB <a href="https://x.com/MarketCoinpedia/status/1921884391242133573">outperformed</a> even high-flying tokens like TRUMP, despite major news events tied to the latter. SHIB is now trading above all major daily and weekly moving averages, with the RSI holding firm at 71, a sign of ongoing strength.
If Shiba Inu breaks resistance at $0.00002148, analysts forecast a move toward $0.00003575, which would mark a 122% rally from recent levels. The price action is also said to mirror the coin's September 2024 breakout setup, further supporting bullish expectations.
Statistics: On-chain growth from Shibarium, including rising accounts, transactions, and new integrations like Zypto, plus Bury 2.0 incentives, are boosting utility and long-term adoption. 
Shibarium, Shiba Inu's Layer-2 scaling solution, is showing strong growth across the board: accounts grew from 240,421 (March 1) to 268,877 (May 10), transactions increased from 931 million to 1.15 billion. 
New integrations such as Zypto and Bury 2.0 are helping drive long-term utility and ecosystem stickiness.
Shibburn data shows the burn rate increasing by 2,267.9% in the past 24 hours, with 13.69 million SHIB burned. A single transaction burned 13.69 million SHIB around seven hours ago.
IntoTheBlock data shows Shiba Inu large transaction volume down by 29.8% in a single day, while daily active addresses were up 0.95%. Transactions greater than $100,000 dropped from 161 to 115 in a single day.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45354990/scottie-pippen-declares-altcoin-season-as-ethereum-xrp-dogecoin-shiba-inu-rally">Scottie Pippen Declares &#8216;Altcoin Season&#8217; As Ethereum, XRP, Dogecoin, Shiba Inu Rally</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Shiba Inu Jumps 27% In 7 Days: What Is Going On?

Truist Securities analyst David Macdonald maintains Fresenius Medical Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMS#NYSE">FMS</a>) with a Hold and raises the price target from $25 to $30.

Truist Securities Maintains Hold on Fresenius Medical Care, Raises Price Target to $30

JP Morgan analyst Richard Shane maintains Starwood Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STWD#NYSE">STWD</a>) with a Overweight and raises the price target from $19 to $19.5.

STWD

JP Morgan Maintains Overweight on Starwood Property Trust, Raises Price Target to $19.5

Truist Securities analyst David Macdonald maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Buy and raises the price target from $82 to $84.

Truist Securities Maintains Buy on CVS Health, Raises Price Target to $84

Legal

Press Releases

DEADLINE ALERT for PACS, HAS, ASML, HUMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

DEADLINE ALERT for PACS, HAS, and ASML: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PACS Group

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of PACS Group, Inc. (PACS) Shareholders

PACS DEADLINE TODAY: ROSEN, A LEADING NATIONAL FIRM, Encourages PACS Group Inc. Investors to Secure Counsel Before Important January 13 Deadline in Securities Class Action - PACS

PACS Group, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. January 13, 2025 Deadline to file Lead Plaintiff Motion

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in PACS Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - PACS

PACS Group, Inc. (NYSE: PACS) Shareholder Notice: Grabar Law Office Is Investigating Claims on Your Behalf

PACS GROUP ALERT: Bragar Eagel & Squire, P.C. is Investigating PACS Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation of PACS Group, Inc. (NYSE: PACS) and Encourages Long-Term PACS Investors to Contact the Firm

Comments

PACS Group

Noticias

Últimas noticias sobre PACS Group (NYSE:PACS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL